Virtuix is no longer just a niche gadget for VR gamers—it’s pushing its full-body movement tech into military training, where multiple U.S. service branches are already testing it. The real question is whether this shift, plus faster ways to turn real-world footage into walkable virtual environments, can turn early pilots into steady demand—or whether funding needs and slow defense rollouts get in the way.Read more

Optimi Health already makes and ships controlled psychedelic medicines to paying clinics, while most rivals are still waiting for approvals. The story hinges on whether a real, insured market can scale fast enough to fill its underused factory—before funding and rule changes become a problem.Read more

Cue Biopharma bets its future on a new allergy drug designed by the same scientist who created Xolair, aiming to make treatment far less frequent for people with chronic hives and other allergic conditions. A key mid-stage trial result is coming soon, and it could either put Cue on big pharma’s radar or expose just how risky this turnaround really is.Read more

Key Takeaways Giftify (GIFT) is building an incentives and rewards platform anchored by CardCash, the nation’s leading secondary gift card marketplace, processing over $154 million in annual transaction volume. The global gift card market is projected at $680 billion in 2026, growing to $1,259 billion by 2031.Read more

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more